A VRC13-like bNAb response is associated with complex escape pathways in HIV-1 envelope.
Vinita R Joshi, Daniel T Claiborne, Melissa L Pack, Karen A Power, Ruchi M Newman, Rebecca Batorsky, David J Bean, Matthew S Goroff, Daniel Lingwood, Michael S Seaman and 2 more
Article in Journal of virology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 97% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
1 citing paper in PubMed, 0 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
12 authors at 4 institutions in 2 countries.
Vinita R JoshiRagon Institute of Mass General, MIT and Harvard, Cambridge, Massachusetts, USA.ORCID 0000-0002-3032-137X
Daniel T ClaiborneRagon Institute of Mass General, MIT and Harvard, Cambridge, Massachusetts, USA.ORCID 0000-0002-2091-1456
Melissa L PackRagon Institute of Mass General, MIT and Harvard, Cambridge, Massachusetts, USA.
Karen A PowerRagon Institute of Mass General, MIT and Harvard, Cambridge, Massachusetts, USA.
Ruchi M NewmanRagon Institute of Mass General, MIT and Harvard, Cambridge, Massachusetts, USA.
Rebecca BatorskyRagon Institute of Mass General, MIT and Harvard, Cambridge, Massachusetts, USA.
David J BeanRagon Institute of Mass General, MIT and Harvard, Cambridge, Massachusetts, USA.
Matthew S GoroffRagon Institute of Mass General, MIT and Harvard, Cambridge, Massachusetts, USA.
Daniel LingwoodRagon Institute of Mass General, MIT and Harvard, Cambridge, Massachusetts, USA.
Michael S SeamanCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
Eric RosenbergDepartment of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
Todd M AllenRagon Institute of Mass General, MIT and Harvard, Cambridge, Massachusetts, USA.ORCID 0000-0002-6609-1318
Ragon Institute of MGH, MIT and Harvard · USBeth Israel Deaconess Medical Center · USHarvard University · USMassachusetts General Hospital · US
Funding
Vaccine Adjuvant/ Delivery Systems CoreP01AI104715 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI IRVINE, DARRELL J · 2013 to 2017
$12.3M
Innate-like BCR activity as a template for universal vaccination against influenza virusR01AI137057 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI CHACKERIAN, BRYCE C, LINGWOOD, DANIEL · 2018 to 2022
$2.6M
Triggering germline-encoded broadly neutralizing antibody responses against influenza virusR01AI153098 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI BATISTA, FACUNDO DAMIAN, LINGWOOD, DANIEL · 2020 to 2023
$2.1M
Systemic coordination of pro-inflammatory immune reactions through dendritic cell-restricted sIL6R biogenesisR01AI155447 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI LINGWOOD, DANIEL · 2021 to 2025
$2.0M
HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) AI04715NIAID NIH HHS P01 AI104715NIAID NIH HHS R01 AI137057NIAID NIH HHS R01 AI153098NIAID NIH HHS R01 AI155447
6 · The paper itself
Abstract
The rational design of HIV-1 immunogens to trigger the development of broadly neutralizing antibodies (bNAbs) requires understanding the viral evolutionary pathways influencing this process. An acute HIV-1-infected individual exhibiting >50% plasma neutralization breadth developed neutralizing antibody specificities against the CD4-binding site (CD4bs) and V1V2 regions of Env gp120. Comparison of pseudoviruses derived from early and late autologous
Indexed as
Broadly Neutralizing AntibodiesHIV InfectionsAIDS VaccinesAmino AcidsCD4 Antigensenv Gene Products, Human Immunodeficiency VirusEpitopesHIV-1HIV AntibodiesHIV AntigensHIV Envelope Protein gp120HIV SeropositivityHumansAIDS VaccinesAmino AcidsBroadly Neutralizing AntibodiesCD4 Antigensenv Gene Products, Human Immunodeficiency VirusEpitopesHIV AntibodiesHIV AntigensHIV Envelope Protein gp120bNAbCD4bsescapeevolutionHIVVRC13
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.
A VRC13-like bNAb response is associated with complex escape pathways in HIV-1 envelope. · full record | Socratic